JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Медицинская радиология и радиационная безопасность. 2021. Том 66. № 5. C.66–77
А.В. Хмелев1,2
АКТУАЛЬНЫЕ АСПЕКТЫ ПРИМЕНЕНИЯ РАДИОФАРМАЦЕВТИЧЕСКИХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ В ПЭТ-ИССЛЕДОВАНИЯХ
1Республиканский исследовательский научно-консультационный центр экспертизы Минобрнауки, Москва.
2Российская медицинская академия непрерывного профессионального образования Минздрава РФ, Москва.
Контактное лицо: Александр Васильевич Хмелев: This email address is being protected from spambots. You need JavaScript enabled to view it.
СОДЕРЖАНИЕ
Введение
1.Требования к радиофармацевтическим лекарственным препаратам
2. Факторы, влияющие на биораспределение в организме
3. Механизмы накопления и локализации
4. Применения в ПЭТ-исследованиях биопроцессов и диагностике
5. Аспекты регулирования обращения
Заключение
Ключевые слова: радиофармацевтический лекарственный препарат, радионуклид, механизмы локализации, ПЭТ
Для цитирования: Хмелев А.В., Актуальные аспекты применения радиофармацевтических лекарственных препаратов в ПЭТ-исследованиях // Медицинская радиология и радиационная безопасность. 2021. Т. 66. № 5. С.66–77.
DOI: 10.12737/1024-6177-2021-66-5-66-77
Список литературы
1.Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT. Berlin: Heidelberg: Springer-Verlag, 2009. 133 p.
2. Saha G.B. Basics of PET Imaging. Physics, Chemistry and Regulation. New York: Springer, 2010. 241 p.
3. Хмелев АВ. Позитронная эмиссионная томография: физико-технические аспекты. М.: Тровант, 2016. 336 с.
4. Zimmermann R.G. Industrial Constraints in the Selection of Radionuclides and the Development of New Radiopharmaceuticals // World J. Nucl. Med. 2008. No. 7. P. 126-34.
5. Qaim M. Development of Cyclotron Radionuclides for Medical Applications: from Fundamental Nuclear Data to Sophisticated Production Technology. In: WTTC15: Proceedings of WTTC15; 2014 Aug 18-21. Prague, Czech Republic, 2014. P. 18-20.
6. Хмелев А.В. Анализ состояния радионуклидного обеспечения позитронной эмиссионной томографии // Мед. радиология и радиационная безопасность. 2019 Т.64, № 6. С. 70-81.
7. Кодина Г.Е., Красикова Р.Н. Методы получения радиофармацевтических препаратов и радионуклидных генераторов для ядерной медицины. М.: Издат. дом МЭИ, 2014. 282 c.
8. Davidson C.D., Phenix C.P., Tai T.C., Khaper N., Lees S.J. Searching for Novel PET Radiotracers: Imaging Cardiac Perfusion, Metabolism and Inflammation // Am. J. Nucl. Med. Mol. Imaging. 2018. V.8, No. 3. P. 200-27. PMID: 30042871. PMCID: PMC6056242.
9. Wadsak W., Mitterhauser M. Basic and Principles of Pharmaceuticals for PET/CT // E.J.R. 2010. No. 73. P. 461-469. DOI: 10.1016/j.ejrad .2009.12.022. PMID: 20181453.
10. Miller P.W., Long N.J., Vilar R., Gee A.D. Synthesis of 11C, 18F, 15O and 13N Radiolabels for Positron Emission Tomography // Angew. Chem. Int. Ed. 2008. No. 47. P. 8998-9033. DOI: 10.1002/anie .200800222. PMID: 18988199.
11. Zimmermann R.G. Why Are Investors not Interested in My Radiotracer? The Industrial and Regulatory Constraints in the Development of Radiopharmaceuticals // Nucl. Med. Biol. 2013. No. 40. P. 155-166. DOI: 10.1016/j.nucmedbio.2012.10.012. PMID: 23218796.
12. Lau J., Rousseau E., Kwon D., Lin K.-S., Bénard F., Chen X. Insight Into the Development of PET Radiopharmaceuticals for Oncology // Cancers. 2020. V.12, No. 5. P. 1312-1365. DOI: 10.3390/cancers12051312. PMID: 32455729. PMCID: PMC7281377.
13. Mourtada F., Sims-Mourtada J., Azhdarinia A., Yang D.J. Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer? // Current Medical Imaging. 2008. V.4, No. 1. P. 28-33. DOI: 10.2174/157340508783502804.
14. Vallabhajosula S., Killeen R.P. Osborne J.R. Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors // Semin. Nucl. Med. 2010. No. 40. P. 220-241. DOI: 10.1053/j.semnuclmed.2010.02.004 PMID: 20513446.
15. Ziessman H., O'Malley J. Nuclear Medicine: the Requisites. Philadelphia: Saunders, 2014. 464 p.
16. Kamkaew A., Ehlerding E.B., Cai W. Nanoparticles as Radiopharmaceutical Vectors // Radiopharmaceutical Chemistry / Eds. Lewis J., Windhorst A., Zeglis B. New York: Springer, Cham, 2019. P. 181-203.
17. Lee Y.S. Radiopharmaceuticals for Molecular Imaging // The Open Nuclear Medicine Journal. 2010. No. 2. P. 178-185.
18. Jeong J.M. Application of a Small Molecule Radiopharmaceutical Concept to Improve Kinetics // Nucl. Med. Mol. Imaging. 2016. No. 50. P. 99-101. DOI: https://doi.org/10.1007/s13139-015-0369-6.
19. Waterhouse R.N. Determination of Lipophilicity and Its Use as a Predictor of Blood-Brain Barrier Penetration of Molecular Imaging Agents // Mol. Imaging. Biol. 2003. V.5, No. 6. P. 376-89. DOI: 10.1016/j.mibio .2003.09.014 PMID: 14667492.
20. Silindir M., Özer A.Y. Recently Developed Radiopharmaceuticals for Positron Emission Tomography (PET) // Fabad. J. Pharm. Sci. 2008. No. 33. P. 153-62.
21. Colom M., Vidal B., Zimmer L. Is there a Role for GPCR Agonist Radiotracers in PET Neuroimaging? // Front. Mol. Neurosci. 2019. No. 12. P. 255-94. DOI: 10.3389/fnmol.2019.00255. PMID: 31680859. PMCID: PMC6813225.
22. Komal S., Nadeem S., Faheem Z., Raza A., Sarwer K., Umer H., et al. Localization Mechanisms of Radiopharmaceuticals. 2020. Available from: https://www.intechopen.com/online-first/localization-mechanisms- of-radiopharmaceuticals. DOI:10.5772/intechopen.94099.
23. Ponto J.A. Mechanisms of Radiopharmaceutical Localization / Ed. Norenberg J. // UNM Сollege of pharmacy. 2012. V.16, No. 4. P. 2-35.
24. Lim M.M.D., Gnerre J., Gerard P. Mechanisms of Uptake of Common Radiopharmaceuticals RadioGraphics Fundamentals: Online Presentation // Radiographics. 2018. V.38, No.5. P. 1550-1551. Available from: https://doi.org/10.1148 /rg.2018180072.
25. Kilian K. 68Ga-DOTA and Analogs: Current Status and Future Perspectives // Rep. Pract. Oncol. Radiother. 2014. No. 19. P. 13-21. DOI: 10.1016/j.rpor.2014.04.016. PMID: 28443194.
26. Huang Y.Y. An Overview of PET Radiopharmaceuticals in Clinical Use: Regulatory, Quality and Pharmacopeia Monographs of the United States and Europe. 2018. Available from: https:// www.intechopen.com /books/nuclear-medicine-physics/an-overview-of-pet-radiopharmaceuticals-in-clinical-use-regulatory-quality-and-pharmacopeia-monograp. DOI:10.5772/intechopen.79227.
27. Perk L.R., Stigter-van Walsum M., Visser G.W., Kloet R.W., Vosjan M.J.W.D., Leemans C.R., et al. Quantitative PET Imaging of Met-Expressing Human Cancer Xenografts with 89Zr-Labelled Monoclonal Antibody DN30 // Eur. J. Nucl. Med. Mol. Imaging. 2008. No. 35. P. 1857-1867. Available from: https://doi.org/10.1007/s00259-008-0774-5
28. Brooks A.F., Drake L.R., Stewart M.N., Cary B.P., Jackson I.M., Mallette D., et al. Fluorine-18 Patents (2009–2015). Part 1. Novel Radiotracers // Pharm. Pat. Anal. 2016. V.5, No.1. P. 17-47. DOI: 10.4155/ppa.15.36. PMID: 26670619. PMCID: PMC5561792.
29. Pagani M., Stone-Elander S., Larsson S.A. Alternative Positron Emission Tomography with Non-Conventional Positron Emitters: Effects of Their Physical Properties on Image Quality and Potential Clinical Applications // Eur. J. Nucl. Med. 1997. V.24, No. 10. P. 1301-1327. DOI: 10.1007/s002590050156. PMID: 9323273.
30. Jødal L., Le Loirec С., Champion С. Positron Range in PET Imaging: Non-Conventional Isotopes // Physics in Medicine and Biology IOP Publishing. 2014. V.59. P. 7419-7434. Available from: https://www.hal .archives-ouvertes.fr/hal-01174227.
31. Jung J., Ahn B.-C. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat. 2018. V.6, No. 2. P. 47-53. DOI: 10.14791/btrt.2018.6.e13.PMID: 30381916. PMCID: PMC6212689.
32. Зыков Е.М., Поздняков А.В., Костеников Н.А. Рациональное использование ПЭТ и ПЭТ-КТ в онкологии // Практическая онкология. 2014. Т.15, № 1. С. 31–6.
33. Lopci E., Grassi I., Chiti A., Nanni C., Cicoria G., Toschi L., et al. PET Radiopharmaceuticals for Imaging of Tumor Hypoxia: a Review of the Evidence // Am. J. Nucl. Med. Mol. Imaging. 2014. V.4, No. 4. P. 365-384. PMID: 24982822. MCID: PMC4074502.
34. Andersson J.D., Halldin C. PET Radioligands Targeting the Brain GABAA/Benzodiazepine Receptor Complex // J. Label. Compd. Radiopharm. 2013. No. 56. P. 196-206. DOI: 10.1002/jlcr.3008. PMID: 24285326.
35. Meisenheimer M., Saenko Yu., Eppard E. Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging- a Lot to Consider. 2019. Available from: https://www.intechopen.com/books/medical- isotopes/gallium-68-radiolabeling-of-radiopharmaceuticals-for-pet-imaging-a-lot-to-consider. IntechOpen. DOI: 10.5772/intechopen.90615.
36. Weineisen M., Schottelius M., Simecek J., Baum R.P., Yildiz .A., Beykan S., et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies // J. Nucl. Med. 2015. V.56, No. 8. P. 1169-1176. PMID: 26089548. DOI: 10.2967/jnumed.115.158550.
37. Werner R.A., Bluemel C., Allen-Auerbach M.S., Higuchi T., Hermann R. 68Gallium- and 90Yttrium-/ 177Lutetium: “Theranostic Twins” for Diagnosis and Treatment of NETs // Ann. Nucl. Med. 2015. No. 29 P. 1-7. DOI: https://doi.org/10.1007/s12149-014-0898-6.
38. Van de Watering F.C.J., Rijpkema M., Perk L., Brinkmann U., Oyen W.J.G., Boerman O.C., et al. Zirconium-89 Labeled Antibodies: a New Tool for Molecular Imaging in Cancer Patients // Biomed. Res. Int. 2014. V.2014. 203601. DOI: 10.1155/2014/203601. PMID: 24991539.
39. Dijkers E.C., Kosterink J.G., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/New ImmunoPET Imaging // J. Nucl. Med. 2009. No. 50. P. 974-981. PMID: 19443585 DOI: 10.2967/jnumed.108.060392.
40. Mahajan S., Divgi C.R. The Role of Iodine-124 Positron Emission Tomography In Molecular Imaging // Clin. Transl. Imaging. 2016. V.4. No. 4. P. 297-306. PMID: 27158012. DOI: 10.1016/j.cpet.2008.05.001.
41. FDA-Approved Radiopharmaceutical // Cardinal Health. 2019. Rev. 21/6.26.20. Available from: https://www.cardinalhealth.com/content/ dam/corp/web/documents/fact-sheet/cardinal-health-fda-approved-radiopharmaceuticals.pdf.
42. Clarke B.N. PET Radiopharmaceuticals: what’s New, what’s Reimbursed, what’s Next? // J. Nucl. Med. Tech. 2018. V.46, No. 1. P. 12-16. PMID: 29438008. DOI: 10.2967/jnmt.117.205021.
43. Зелинская Е. Радиофармацевтика – уникальное направление фармацевтической индустрии // Новости GMP. 2018. Т.2, № 16. С. 55-70.
PDF (RUS) Полная версия статьи
Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.
Финансирование. Исследование не имело спонсорской поддержки.
Участие авторов. Cтатья подготовлена с равным участием авторов.
Поступила: 23.12.2020.
Принята к публикации: 20.01.2021.